Veronica Miller, PhD, is an Adjunct Professor at Berkeley Public Health and Director of the Forum for Collaborative Research, a collaboration between industry, regulatory agencies, patients, and public health/clinical researchers to advance regulatory science and accelerate drug development in areas of unmet medical need. The Forum applies innovative translational medicine approaches to specific disease areas, such as viral infections, chronic diseases (steatotic and cholestatic disease of the liver), and ocular diseases requiring multi-modal approaches to generate solutions to high-prevalence complex, as well as rare, diseases. The approach involves multidisciplinary teams of experts in Public Health, Medicine, Biology, Statistics, Computer Science, Data Science, and Regulatory Science to effect the last but crucial step in translational medicine to improve access to therapeutics and diagnostics around the world. The Forum’s Data and Analysis Center is a cross-industry collaborative data-sharing platform to maximize the usefulness of clinical trial-generated data, including tissue/organ imaging, histopathology, radiology, and biomarkers spanning diverse contexts of use. The Forum DAC is made possible by Berkeley’s commitment to supporting infrastructure for sensitive patient-level data, and a forward-looking Office of Industry Alliance. The Forum offers unique educational opportunities for students and fellows interested in biotechnology. Veronica Miller is committed to the education of the next generation of scientists through hands-on learning complemented by online and on-campus courses. She has over 145 peer-reviewed publications.

Selected recent publications:

1. Zannad F, Sanyal A, Butler J, Miller V, Harrison SA. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease. Nature Medicine 2024; 10.1038/s41591-024-03223-z.
2. Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN for the CMF Definitions Working Group. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from Transplant Associated Virus Infections Forum. Clin Inf Dis. 2024; 10.1093/cid/ciae321.
3. Murdock N, Alajaji NE, Schaefer R, Boone CA, Campo RE, Dore GJ, Gandhi M, Gorospe JR, Gulick RM, Hodder SL, Liu J, Rhee MS, Rooney JF, Vannappagari V, Wilkin T, Miller V. Long-acting HIV treatments: study design, logistics, and access. Open Forum Infectious Diseases 2024; 10.1093/ofid/ofae337.
4. Zannad F, Sanyal A, Butler J, Ferreira JP, Girerd N, Miller V, Pandey A, Parikh CR, Ratziu V, Younossi ZM, Harrison SA. MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials. Journal of Internal Medicine 2024; 10.1111/joim.13793.
5. Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S,  Miller V, Lenz O. Chronic hepatitis B finite treatment: similar and different concerns with new drug classes. Clin Inf Dis 2023; 10.1093/cid/ciad506.
6. Wedermeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor J, Kessler HH, Lenz O, Luetgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P. HDV RNA assays: performance characteristics, clinical utility, and challenges. Hepatology 2023; 10.1097/HEP.0000000000000584.
7. Kidwell KM, Roychoudhury S, Wendelberger B, Scott J, Moroz T, Yin S, Majumder M, Zhong J, Huml RA, Miller V. Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles. Orphanet J Rare Dis. 2022; 17(1): 186.10.1186/s13023-022-02342-5.
8. Zoulim F, Zlotnick A, Buchholz S, Donaldson E, Fry J, Gaggar A, Hu J, Kann M, Lenz O, Lin K, Mani N, Nassal M, Delaney W, Wang S, Westman G, Miller V, Janssen HLA. Nomenclature of HBV core protein-targeting antivirals. Nat Rev Gastroenterol Hepatol 2022; 19(12): 748-750.10.1038/s41575-022-00700-z.
9. Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden DV, Hughes JP, Murray J, Robertson MN, Zinserling J, Lau J, Miller V. Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project. Clin Pharmacol Ther. 2022; 10.1002/cpt.2830.
   
10. Imlay H, Baum P, Brennan DC, Hanson KE, Hodges MR, Hodowanec AC, Komatsu TE, Ljungman P, Miller V, Natori Y, Nickeleit V, O'Rear J, Pikis A, Randhawa PS, Sawinski D, Singh H K, Westman G, Limaye AP. Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials. Clin Inf Dis. 2022; 75(7): 1210-1216.10.1093/cid/ciac071.

For a full CV and additional publications: click here

Email:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it